<![CDATA[eVOLVE-Lung02 Trial of Volrustomig Discontinued in Metastatic NSCLC]]>
Phase 3negativevolrustomigchemotherapyNegative
AI Analysis
Summary
The Phase 3 eVOLVE-Lung02 trial of volrustomig in combination with chemotherapy has been discontinued in metastatic NSCLC after an independent committee determined the treatment was unlikely to improve patient survival.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Independent committee concluded that volrustomig plus chemotherapy was unlikely to improve survival
Importance:8/10
Sentiment:
-0.90
Phase 3 discontinuationoncologyNSCLCtrial failurenegative efficacy
Read the original article
Published by Cancer Network on August 17, 2026 7:00 PM